SCHEMBL975246

SCHEMBL975246

O=C(O)/C=C/C1=CC=CCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 5/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA4 P22748 3/20 0.34
CA12 O43570 2/20 0.34
AKR1B10 O60218 2/20 0.34
CA3 P07451 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975247 1.00 HCAR2 (0.36) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL7144454 0.84 CYP1A2 (0.33) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL7144449 0.84 CYP1A2 (0.33) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL7144448 0.84 CYP1A2 (0.33) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL19688849 0.83 GLA (0.37) KDM4EMEN1ALDH1A1LMNAGLA
SCHEMBL183861 0.80 HCAR2 (0.39) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL6446355 0.80 HCAR2 (0.39) HCAR2HDAC3HDAC4HDAC1HDAC7
SCHEMBL10378479 0.77
SCHEMBL21156016 0.75 ALDH1A1 (0.40) CYP3A4MAPK1TSHRMEN1ALDH1A1
SCHEMBL3133219 0.74 HCAR2 (0.34) HCAR2HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268614-B1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO KK (JP) 2013-05-15 EP claimed
US-8258340-B2 Method for producing β-mercapto carboxylic acids SHOWA DENKO K.K. (JP) 2012-09-04 US claimed
US-20110015436-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2011-01-20 US claimed
EP-2268614-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS Showa Denko K.K. (JP) 2011-01-05 EP claimed
WO-2009113711-A1 METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2009-09-17 WO claimed
US-11834404-B2 Derivatives of sulindac can protect normal cells against oxidative damage UNIVERSITY OF SOUTH ALABAMA (US) 2023-12-05 US disclosed
US-20220106250-A1 DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE UNIVERSITY OF SOUTH ALABAMA (US) 2022-04-07 US disclosed
US-11186534-B2 Derivatives of sulindac can protect normal cells against oxidative damage UNIVERSITY OF SOUTH ALABAMA (US) 2021-11-30 US disclosed
US-20200095184-A1 DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE UNIVERSITY OF SOUTH ALABAMA (US) 2020-03-26 US disclosed
WO-2018170410-A1 DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE UNIVERSITY OF SOUTH ALABAMA (US) 2018-09-20 WO disclosed
EP-2268614-B1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO KK (JP) 2013-05-15 EP disclosed
US-8258340-B2 Method for producing β-mercapto carboxylic acids SHOWA DENKO K.K. (JP) 2012-09-04 US disclosed
US-20110015436-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2011-01-20 US disclosed
EP-2268614-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS Showa Denko K.K. (JP) 2011-01-05 EP disclosed
WO-2009113711-A1 METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834404-B2 Derivatives of sulindac can protect normal cells against oxidative damage PRDX3, PRDX5, SQOR HCAR2 1908/4885HDAC3 463/4885HDAC4 1558/4885
US-20200095184-A1 DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE PRDX3, PRDX5, SQOR HCAR2 1908/4885HDAC3 463/4885HDAC4 1558/4885
US-20110015436-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS CBS, ALDH7A1, CBR1 HCAR2 174/4885HDAC3 2244/4885HDAC4 3957/4885
US-20220106250-A1 DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE PRDX3, PRDX5, SQOR HCAR2 1908/4885HDAC3 463/4885HDAC4 1558/4885
US-11186534-B2 Derivatives of sulindac can protect normal cells against oxidative damage PRDX3, PRDX5, SQOR HCAR2 1908/4885HDAC3 463/4885HDAC4 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.